News | Latest Breaking News Stories & Headlines

Novartis said it plans to build six new manufacturing plants in the US

Novartis plans to invest $23 billion in US sites

Swiss drugmaker Novartis said today it plans to spend $23 billion to build and expand 10 facilities in the US, as it grapples with renewed threats of drug import duties from the Trump administration.

Business • 11 Apr

Swiss pharmaceutical giant Novartis has agreed a deal to buy Anthos Therapeutics, a biopharma firm

Novartis buys Blackstone's Anthos for up to $3.1 billion

Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost its cardiovascular business.

Business • 11 Feb

Novartis has raised its sales guidance to 6% annual growth up to 2028

Novartis raises sales guidance up to 2028

Novartis raised its medium-term sales guidance to 6% annual growth up to 2028, driven by strong momentum of launched drugs and the prospect of upcoming launches.

Business • 21 Nov 24

Novartis said its Q1 revenues climbed 10% to a better-than-expected $11.83 billion

Novartis lifts guidance after Q1 results beat forecasts

Swiss drugmaker Novartis has today raised its full-year guidance after reporting better-than-expected first-quarter results.

Business • 23 Apr 24

The medium-term target, which excludes any foreign exchange effects, is mainly driven by six drugs.

Novartis raises sales growth target to 5% a year

Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of its generics business.

Business • 28 Nov 23

Novartis said its third-quarter group sales rose 12% to $11.78 billion

Novartis lifts 2023 earnings forecast for third time

Switzerland's Novartis has today raised its full-year earnings forecast for the third time, citing cost cuts and higher-than-forecast prices for a multiple sclerosis (MS) drug.

Business • 24 Oct 23

The transaction is expected to close in the second half of 2023

Novartis to buy Seattle-based Chinook for up to $3.5bn

Novartis has agreed to acquire Seattle-based biotech firm Chinook Therapeutics for up to $3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare severe kidney disease.

Business • 12 Jun 23

Novartis has just completed the repurchase of 213 million of its shares in the period between March 2020 and March 10 2023

Novartis launches new $11 billion share buyback

Novartis has formally launched its new share buyback programme where it could spend up to 10 billion Swiss francs ($10.90 billion) repurchasing its shares over the next three years.

Business • 13 Mar 23

Novartis to pay $245m to end antitrust cases on Exforge

Novartis said today it will pay $245m to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the US of generic versions of its Exforge hypertension drug.

Business • 29 Dec 22

Novartis said the changes will take place over the next two years at its Global Service Centre at Elm Park in Dublin

Novartis plans to cut up to 400 jobs at Dublin site

Pharmaceutical company Novartis has announced plans to cut up to 400 jobs from its Dublin operations.

Business • 13 Oct 22

Novartis sells Ringaskiddy plant to Sterling Pharma

Novartis has sold its manufacturing plant in Ringaskiddy in Cork to global contract development and manufacturing business Sterling Pharma Solutions.

Business • 01 Mar 22

The update comes weeks after Novartis said it would sell its stake in Roche

Novartis expects new drugs to boost sales

Novartis has said it is confident of delivering annual revenue growth of 4% or higher until 2026, as it banks on multi-billion dollar sales of experimental and approved drugs including arthritis and psoriasis medicine Cosentyx.

Business • 02 Dec 21

Novartis said its sales in the three months to June rose 14% to $12.96 billion

Novartis profit tops expectations as Covid impact ebbs

Swiss drugmaker Novartis has today beaten second-quarter sales and profit expectations, but kept its 2021 guidance unchanged as disruption from the coronavirus pandemic waned.

Business • 21 Jul 21

The Swiss drugmaker's first-quarter profit fell below analyst expectations

Novartis catches chill as mask wearing keeps flu at bay

Mask wearing during the pandemic kept the flu largely at bay this year, dampening Novartis's generic cough medicines business and helping drag the Swiss drugmaker's first-quarter profit below analyst expectations.

Business • 27 Apr 21

Novartis does not have vaccines in the works for Covid-19

Novartis Q4 sales, core net income trail expectations

Switzerland's Novartis said delays of two blockbuster hopefuls - heart drug Leqvio that cost it $10 billion and $2.1m-per-patient Zolgensma - remain in regulators' hands, dragging on sales already hit by the pandemic.

Business • 26 Jan 21

Under the terms of the deal, 100 Novartis staff working at the International Service Laboratory in Ringaskiddy will transfer to SGS

Novartis deal with SGS secures 100 Ringaskiddy jobs

Novartis has today announced that Swiss firm SGS will buy and operate the assets of its International Service Laboratory on the Ringaskiddy campus, securing jobs at the Cork facility.

Business • 12 Jan 21

Novartis is running a 440-person trial of its generic drug hydroxychloroquine in Covid-19 patients

Novartis sales, profits rise on Covid-19 buying rush

Novartis saw its first-quarter sales climb as hospitals and patients stocked up on drugs to avoid being left short during the coronavirus crisis, lifting profits for the Swiss drugmaker.

Business • 28 Apr 20

Novartis said its third-quarter core net income rose 17% to $3.2 billion

Novartis hikes 2019 outlook as gene therapy shines

Novartis has today boosted its full-year targets, as sales of medicines including psoriasis drug Cosentyx and gene therapy Zolgensma helped the Swiss drugmaker surpass analysts' third-quarter expectations.

Business • 22 Oct 19

Novartis will close in Ringaskiddy by mid-2022

320 jobs to go at Novartis in Cork

A total of 320 jobs are to go at Novartis in Co Cork as it closes one of its production buildings by mid-2022.

Ireland • 23 Oct 19

The Swiss company said it was stockpiling to maintain the delivery of the 120 million packs it exports to Britain from Europe each year

Novartis urges UK to secure drug supplies before Brexit

Drug company Novartis has called on Britain to urgently guarantee the movement of drugs in the event of a chaotic Brexit.

Business • 25 Jan 19

Germany's Federal Institute for Drugs and Medical Devices has ordered the country's main drug industry associations to gather information on the effect of a no-deal Brexit

Germany advises drug makers to examine supply chain

German drug makers have been asked by the government to examine their supply chains for any vulnerability that could cause shortages of essential drugs in the event that Britain leaves the European Union without a Brexit deal.

Business • 29 Aug 18

GSK CEO Emma Walmsley said today's deal will accelerate efforts to improve its performance

GSK buys Novartis stake in consumer healthcare venture

GlaxoSmithKline said today it will buy Novartis's 36.5% stake in their consumer healthcare joint venture for $13 billion in cash, and will also begin a strategic review of some other businesses.

Business • 27 Mar 18

Novartis is the world's biggest prescription drugmaker

Novartis warns its 2016 profit may fall

Novartis has warned that its profit may decline this year as it ramps up marketing spending on new heart failure drug Entresto after a disappointing start for the medicine.

Business • 19 Jul 16

GSK sold its oncology business to Novartis for $16bn

GSK sees quarterly profit soar after Novartis deal

British drugmaker GlaxoSmithKline said its net profit rocketed in the first quarter on a vast exceptional gain following a deal with Swiss peer Novartis.

Business • 06 May 15

GlaxoSmithKline plans to buy Novartis's global human vaccines business and tie up the two firms' consumer health businesses

EU gives conditional backing to Novartis, GSK deal

The EU has approved mega deals involving drugmakers Novartis and GlaxoSmithKline, provided they sell off assets in the vaccines and consumer health businesses.

Business • 28 Jan 15